Literature DB >> 19138318

Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation.

Rosana Tamanaha1, Cléber P Camacho, Alexandre C Pereira, Adriana M Alvares da Silva, Rui M B Maciel, Janete M Cerutti.   

Abstract

CONTEXT: We previously described a six-generation family with G533C RET mutation and medullary thyroid carcinoma, in the largest family reported do date. Of particular interest, phenotype variability regarding the age of onset and clinical presentation of the disease, was observed.
OBJECTIVE: We evaluate whether single SNPs within RET oncogene or haplotype comprising the RET variants (defined by Haploview) could predispose to early development of MTC in this family and influence the clinical manifestation.
DESIGN: Eight SNPs were selected based on their previous association with the clinical course of hereditary or sporadic MTC, in particular promoting an early onset of disease. The variants were initially tested in 77 G533C-carriers and 100 controls using either PCR-direct sequencing or PCR-RFLP. Association between a SNP or haplotype and age at diagnosis or presence of lymph node metastasis was tested in 34 G533C-carries with MTC. Different bioinformatic tools were used to evaluate the potential effects on RNA splicing.
RESULTS: An association was found between IVS1-126G > T and age at diagnosis. The variant [IVS8 +82A > G; 85-86 insC] was associated with the presence of lymph node metastases at diagnosis. In silico analysis suggested that this variant may induce abnormal splicing. This in silico analysis predicted that the [IVS8 +82A > G; 85-86 insC] could alter the splicing by disrupting and/or creating exonic splicing enhancer motifs.
CONCLUSIONS: We here identified two RET variants that were associated with phenotype variability in G533C-carriers, which highlights the fact that the modifier effect of a variant might depend on the type of mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138318     DOI: 10.1111/j.1365-2265.2008.03491.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.

Authors:  Vasudha Mishra; Pradnya Kowtal; Pallavi Rane; Rajiv Sarin
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

Review 2.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

3.  Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families.

Authors:  F O F Valente; M R Dias da Silva; C P Camacho; I S Kunii; A U Bastos; C C N da Fonseca; H P C Simião; R Tamanaha; R M B Maciel; J M Cerutti
Journal:  J Endocrinol Invest       Date:  2013-05-30       Impact factor: 4.256

Review 4.  Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms.

Authors:  Lucieli Ceolin; Débora R Siqueira; Mírian Romitti; Carla V Ferreira; Ana Luiza Maia
Journal:  Int J Mol Sci       Date:  2011-12-27       Impact factor: 5.923

5.  Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis.

Authors:  Vasudha Mishra; Pradnya Kowtal; Pallavi Rane; Rajiv Sarin
Journal:  Cancer Med       Date:  2019-08-13       Impact factor: 4.452

6.  The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association.

Authors:  Laura Fugazzola; Simone De Leo; Michela Perrino
Journal:  Thyroid Res       Date:  2013-03-14

Review 7.  Personalized medicine: caught between hope, hype and the real world.

Authors:  Marc Dammann; Frank Weber
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

8.  Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome.

Authors:  Nikoletta Lendvai; Miklos Tóth; Zsuzsanna Valkusz; Gabriella Bekő; Nikolette Szücs; Eva Csajbók; Péter Igaz; Balázs Kriszt; Balázs Kovács; Károly Rácz; Attila Patócs
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

9.  Effect of 3'UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma.

Authors:  Lucieli Ceolin; Mirian Romitti; Débora Rodrigues Siqueira; Carla Vaz Ferreira; Jessica Oliboni Scapineli; Beatriz Assis-Brazil; Rodolfo Vieira Maximiano; Tauanne Dias Amarante; Miriam Celi de Souza Nunes; Gerald Weber; Ana Luiza Maia
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

10.  Variability in Medullary Thyroid Carcinoma in RET L790F Carriers: A Case Comparison Study of Index Patients.

Authors:  Jes Sloth Mathiesen; Søren Grønlund Nielsen; Åse Krogh Rasmussen; Katalin Kiss; Karin Wadt; Anne Pernille Hermann; Morten Frost Nielsen; Stine Rosenkilde Larsen; Klaus Brusgaard; Anja Lisbeth Frederiksen; Christian Godballe; Maria Rossing
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-28       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.